Disposition (Details) - Biodefense Business [Member]	Nov. 04, 2015 USD ($) shares
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sales of business, number of common stock shares eligible to receive | shares	1,150
Royalties receivable percentage on net sales	15.00%
Maximum [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash payments from Nanotherapeutics | $	$ 4,500,000